Eurohealth RESEARCH • DEBATE • POLICY • NEWS Volume 14 Number 2, 2008 Pharmaceutical policy: cost containment and its impact Pricing pharmaceuticals Generic medicines: savings to health care systems? Innovation and regulation in the pharmaceutical sector Orphan drugs: challenges for economic evaluation • Public-private partnerships for health and development Pharmaceutical pricing in France • Parallel trade and cost control • Access to medicines in sub-Saharan Africa Ensuring affordability, safeguarding Eurohealth innovation LSE Health, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom C Health care systems are under continuous pressure to fax: +44 (0)20 7955 6090 www.lse.ac.uk/LSEHealth deliver high quality services that meet ever higher public expectations. They are also acutely aware of the Editorial Team need to contain costs. The direction of pharmaceutical EDITOR: policy is one challenge; for instance what pricing David McDaid: +44 (0)20 7955 6381 email:
[email protected] mechanisms help facilitate greater value for money? As O FOUNDING EDITOR: Thomas Ceuni and Jim Attridge note in respective Elias Mossialos: +44 (0)20 7955 7564 articles in this issue of Eurohealth, the benefits of email:
[email protected] pharmaceutical innovation to Europe are substantial; DEPUTY EDITORS: but in the prevailing economic climate how can Sherry Merkur: +44 (0)20 7955 6194 email:
[email protected] Europe protect and nourish these industries and Philipa Mladovsky: +44 (0)20 7955 7298 M email: